Rudolph Elisabeth, Dyckhoff Gerhard, Becher Heiko, Dietz Andreas, Ramroth Heribert
Institute of Public Health, University of Heidelberg, Im Neuenheimer Feld 324, 69120, Heidelberg, Germany.
Eur Arch Otorhinolaryngol. 2011 Feb;268(2):165-79. doi: 10.1007/s00405-010-1395-8. Epub 2010 Oct 19.
Laryngeal cancer is the second most common cancer of the respiratory tract with a relative 5-year survival over all tumour sites in the USA (61.6%; SEER 2009), which is much better than other head and neck cancers. The aim of this paper is to review and summarise data on the survival of laryngeal cancer patients. Literature search was conducted to identify articles in PubMed up to June 2009. Thirty studies with different study aims including sufficient information on survival of laryngeal cancer patients were identified. The 5-year overall survival ranged from 0 to 100%, depending on the T- and N-category, therapeutic approach and tumour location. The involvement of other factors such as genetics, nutrition and lifestyle habits remains uncertain. Our meta-analysis on a subgroup of published studies yielded an overall 5-year relative survival rate of 64.2% (95% confidence interval 63.7-64.7%). Different study aims and patient selection criteria prohibit general conclusions. However, this review may provide an actual picture of the complexity of factors influencing the survival of laryngeal cancer patients.
喉癌是呼吸道第二常见的癌症，在美国所有肿瘤部位中其相对5年生存率为61.6%（监测、流行病学和最终结果项目，2009年），这比其他头颈癌要好得多。本文旨在回顾和总结喉癌患者生存情况的数据。通过文献检索在截至2009年6月的PubMed数据库中查找相关文章。确定了30项具有不同研究目的且包含喉癌患者生存足够信息的研究。5年总生存率在0%至100%之间，具体取决于T分期和N分期、治疗方法以及肿瘤位置。其他因素如遗传学、营养和生活习惯的影响仍不确定。我们对一组已发表研究进行的荟萃分析得出总体5年相对生存率为64.2%（95%置信区间63.7 - 64.7%）。不同的研究目的和患者选择标准使得无法得出一般性结论。然而，本综述可能会呈现出影响喉癌患者生存的各种因素复杂性的实际情况。
